{"title":"Determining Extracellular Water Effects in Mild and Severe COVID-19 Pneumonia Clinical Course by using the Bioimpedance Method","authors":"Z. Çavuş, Ayse Vahaboglu, U. Turkmen, Habibe Vural, Döndü Genç Moralar","doi":"10.4274/haseki.galenos.2023.9008","DOIUrl":null,"url":null,"abstract":"Aim: Coronavirus disease-2019 (COVID-19) pneumonia is characterized by a clinical picture showing similar features in severe patients. Some studies evaluate the pathophysiology, prognosis, and treatment of COVID-19 pneumonia. Different laboratory tests have been used to assess the severity and prognosis of rigorously ill COVID-19 patients in addition to clinical and radiological findings. There is no precise indicator for predicting prognosis. We aimed to analyze disease severity by using extracellular water (ECW) measurements. Methods: Extracellular water values and cardiac parameters as cardiac output (CO), and stroke volume (SV) measurements of patients were performed using a non-invasive, easy-to-use, validated device non-invasive cardiac system (NICaS) within the first 2 h after admission. Hemodynamic parameters and ECW values were measured by connecting the NICaS device to make 12 measurements for 2 h at 5 min intervals during admission to service and intensive care patients. Results: Comparing the ward and intensive care groups, there was not any statistically significant difference found between demographic data and ECW, SV, and CO measurements. Conclusion: Although we could not find a statistically significant difference between our measurements, we believe that the NICaS device can play a significant role in the fluid treatment of COVID-19 patients. © 2023 by the Istanbul Haseki Training and Research Hospital.","PeriodicalId":42416,"journal":{"name":"Haseki TIp Bulteni-Medical Bulletin of Haseki","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haseki TIp Bulteni-Medical Bulletin of Haseki","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/haseki.galenos.2023.9008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
生物阻抗法测定轻、重度COVID-19肺炎临床病程中细胞外水效应
目的:冠状病毒病-2019 (COVID-19)肺炎在重症患者中表现出类似的临床特征。一些研究评估了COVID-19肺炎的病理生理、预后和治疗。除了临床和放射学检查外,还使用了不同的实验室检查来评估COVID-19重症患者的严重程度和预后。没有准确的指标预测预后。我们的目的是通过细胞外水(ECW)测量来分析疾病的严重程度。方法:在入院后的前2小时内,使用无创、易于使用、经过验证的无创心脏系统(NICaS)测量患者的细胞外水值和心脏参数,如心输出量(CO)和卒中量(SV)。在住院和重症监护患者入院时,通过连接NICaS装置测量血流动力学参数和ECW值,每隔5分钟测量2小时12次。结果:比较病房组和重症监护组,人口学数据与ECW、SV和CO测量值之间无统计学差异。结论:虽然我们的测量值之间没有统计学上的差异,但我们认为NICaS装置在COVID-19患者的液体治疗中可以发挥重要作用。©伊斯坦布尔Haseki培训和研究医院。
本文章由计算机程序翻译,如有差异,请以英文原文为准。